Chronic myelogenous leukaemia (CML) can progress from a slow growing chronic phase to an aggressive blast crisis phase 1 , but the molecular basis of this transition remains poorly understood.
Here we have used mouse models of CML 2, 3 to show that disease progression is regulated by the Musashi-Numb signalling axis 4, 5 . Specifically, we find that the chronic phase is marked by high levels of Numb expression whereas the blast crisis phase has low levels of Numb expression, and that ectopic expression of Numb promotes differentiation and impairs advanced-phase disease in vivo. As a possible explanation for the decreased levels of Numb in the blast crisis phase, we show that NUP98-HOXA9, an oncogene associated with blast crisis CML 6, 7 , can trigger expression of the RNAbinding protein Musashi2 (Msi2) , which in turn represses Numb. Notably, loss of Msi2 restores Numb expression and significantly impairs the development and propagation of blast crisis CML in vitro and in vivo. Finally we show that Msi2 expression is not only highly upregulated during human CML progression but is also an early indicator of poorer prognosis. These data show that the Musashi-Numb pathway can control the differentiation of CML cells, and raise the possibility that targeting this pathway may provide a new strategy for the therapy of aggressive leukaemias.
Chronic myelogenous leukaemia (CML) is initiated by the BCR-ABL translocation, which leads to myeloid cell expansion while allowing differentiation [8] [9] [10] [11] . Secondary translocations such as NUP98-HOXA9 or AML1-EVI1, or mutations in p53 or INK4A/ARF, trigger progression through an accelerated phase to a blast crisis phase, with progressive loss of the capacity to differentiate 1 . Although blast crisis CML is, in part, more aggressive because of arrested differentiation, the pathways that underlie this arrest remain poorly understood. To determine whether CML progression may be driven by reversal of signals that regulate differentiation during normal development, we focused on Numb 4 , a molecule that can be inherited differentially during asymmetric division and specify a committed fate [12] [13] [14] [15] [16] .
To determine whether Numb regulates leukaemia progression we used mouse models representing chronic phase and myeloid blast crisis CML. Chronic disease was generated by infecting haematopoietic stem-cell-enriched populations (c-Kit 1 Lin 2 Sca-1 1 or KLS) with BCR-ABL and transplanting them into irradiated recipient mice 2,3 . Myeloid blast crisis was modelled by transplanting KLS cells transduced with BCR-ABL and NUP98-HOXA9 (refs 6, 7, 17) . Using these we found that Numb was expressed at significantly lower levels in the blast crisis phase compared with the chronic phase ( Fig. 1a-c) . The decreased expression of Numb in the blast crisis phase indicated that keeping Numb at low levels may be essential for maintaining an immature state and that increasing its levels could trigger differentiation and inhibit disease progression. To test this possibility, haematopoietic cells were infected with BCR-ABL and NUP98-HOXA9 together with either control vector or Numb, transplanted and leukaemia progression monitored. A total of 83% of control mice developed leukaemia compared with 63% of those transplanted with Numb-expressing cells ( Fig. 1d ). Notably, leukaemias that developed in the presence of Numb were more differentiated ( Fig. 1e , f) and unable to propagate disease efficiently (93% versus 20%, Fig. 1g ) or infiltrate secondary organs (Fig. 1h , i and Supplementary Fig. 1 ); no signs of leukaemia were detected in mice that survived ( Fig. 1j and Supplementary Fig. 1 ). Numb also impaired propagation of fully established leukaemias and markedly reduced the frequency of cancer stem cells ( Supplementary Fig. 2 ). These data show that continual repression of Numb is essential for maintenance of blast crisis CML, and that increasing the levels of Numb can inhibit disease.
Because Numb can antagonize Notch signalling in several systems 13, 18, 19 , we tested whether Numb and Notch had a reciprocal relationship in CML. Notch signalling was elevated in blast crisis CML ( Supplementary Fig. 3 ), and its inhibition via dominant negative Xenopus Suppressor of Hairless (dnXSu(H)) delivery or through conditional deletion of Rbpj paralleled the effects of Numb and led to reduced incidence and propagation of blast crisis CML ( Supplementary Fig. 4 ). Furthermore, levels of p53, another Numb target 20 , were higher in Numb-expressing blast crisis CML ( Supplementary Fig. 5a ). In the absence of p53, Numb was unable to affect leukaemic cell growth in vivo or in vitro ( Supplementary Fig.  5b -f), indicating that Numb's effects are in part dependent on p53.
The observation that Numb repression was critical for the maintenance of blast crisis CML led us to seek the mechanism by which Numb may be downregulated in this context. We focused on the RNA-binding protein Musashi (Msi), which has been shown in the nervous system to repress Numb by binding the 39 untranslated region (UTR) of the transcript 21 . Msi was originally identified in Drosophila as a regulator of asymmetric division 5, 22 and its expression has been associated with stem and progenitor cells in several tissues 23, 24 . In the haematopoietic system we found that Msi2 was expressed at much higher levels than Msi1 (Fig. 2a ), and was particularly elevated in stem cells ( Fig. 2b ). Paralleling this, Msi2 expression was tenfold higher in the more immature blast crisis CML (Fig. 2c ); this pattern held true even in matched lineage-negative fractions ( Fig. 2d ), indicating that Msi2 upregulation in the advanced phase is not simply a consequence of altered cellular composition. Finally, expression of Msi2 was most enriched in the lineage-negative fraction of blast crisis CML ( Fig. 2e ). These data indicate that Msi2 expression associates predominantly with normal haematopoietic stem cells and the most immature fraction of leukaemic cells.
Because Msi2 and Numb were expressed in a reciprocal pattern, we tested whether Msi2 could repress Numb during leukaemogenesis. Expression of Msi2 in chronic phase CML cells led to downregulation of Numb ( Fig. 2f, g) . Furthermore, NUP98-HOXA9 could also activate this cascade by increasing expression of Msi2 (Fig. 2h ). Because NUP98-HOXA9 initiates transformation through HoxA9-mediated DNA binding and transcription, we tested whether HoxA9 could bind the Msi2 promoter and activate its expression directly. Chromatin immunoprecipitation revealed that HoxA9 was associated with the putative HoxA9-binding element we identified at 25.7 kb ( Fig. 2i-l ). NUP98-HOXA9 expression was also able to induce Msi2 reporter activity in KLS cells ( Fig. 2m and Supplementary Fig. 6a ). These data show that Msi2 can be upregulated by NUP98-HOXA9 and subsequently contribute to blast crisis CML by repressing Numb.
To test if Msi2 is required for the development of blast crisis CML, we used a mouse in which the Msi2 gene was disrupted by a gene-trap (Gt) vector 25 ( Supplementary Fig. 6a, b ). Msi2 mutant mice were viable, albeit smaller and less frequent than predicted (Msi2 1/1 :Msi2 1/Gt :Msi2 Gt/Gt 5 38:66:19, P 5 0.038), and showed a two-three-fold reduction in the frequency ( Fig. 3a ) and absolute number (data not shown) of KLS cells. Additionally, loss of Msi2 led to significantly impaired leukaemia growth in vivo (Fig. 3b , 93% for control versus 57% for Msi2 Gt/Gt ).
To determine whether inhibiting Msi2 could have an impact on the growth of established CML, and to rule out the possibility that the reduced incidence of leukaemia in gene-trap mutants was due to developmental defects, Msi expression was targeted using an alternative short hairpin (sh)RNA approach ( Supplementary Fig. 7a ). Delivery of Msi2 shRNAs (shMsi) into established blast crisis CML cells increased Numb expression (data not shown) and reduced leukaemia growth in vitro ( Fig. 3c and Supplementary Fig. 7b -e) and in vivo ( Fig. 3d ). Further, the majority of leukaemias that occurred in the presence of shMsi were more differentiated ( Fig. 3e ) and impaired in their ability to propagate disease ( Fig. 3f , 88% control versus 25% shMsi). These data show that Msi2 is important for the establishment and continued propagation of blast crisis CML.
Finally, we examined whether MSI2 was aberrantly upregulated during human leukaemia progression. MSI2 was tracked in 30 patient samples from repositories in Korea and the United Kingdom, and found to be expressed at significantly higher levels in blast crisis CML (Fig. 4a, b ). To determine if this reflected a general pattern in human CML progression, we examined the expression of MSI2 and associated genes in 90 patient samples from banks in the United States 26 . Microarray analysis revealed a marked upregulation of MSI2 in every patient during CML progression (Fig. 4c ). Furthermore, NUMB was downregulated in a majority of blast crisis patients (Fig. 4d) . Notably, our mouse model was driven by NUP98-HOXA9 as a second hit, whereas human blast crisis CML patients harbour a variety of secondary mutations. Because Msi2 could be regulated by HoxA9 expression in the mouse model of CML, we examined whether HOXA9 was upregulated in blast crisis CML samples. The observation that a majority of patient samples had elevated levels of HOXA9 (Fig. 4e ) may explain how MSI2 becomes upregulated in advanced stage disease regardless of the nature of the second hit. Notch signalling targets HES1 and TRIB2 were also elevated in a number of blast crisis patient samples ( Fig. 4f and Supplementary Fig. 8 ), consistent with other independent reports 27 .
Because the highest MSI2 expression was observed in blast crisis patients, where treatment outcomes are extremely poor, and because a range of expression was observed in both chronic and accelerated phase CML, we tested whether MSI2 expression correlated with outcome after allogeneic transplantation. Patients were divided into two groups based on median expression of MSI2. Among 37 chronic phase patients with available outcomes (9 relapses), increased MSI2 expression was associated with a higher risk of relapse (hazard ratio 5 4.35; 95% confidence interval, 0.90-21.06, P 5 0.07). Additionally, among 13 accelerated phase patients with available outcomes (6 deaths and 3 relapses), increased MSI2 expression was not only associated with higher risk of relapse (all relapses occurred in the increased MSI2 group, P 5 0.06) but also with higher risk of death (hazard ratio 5 6.76; 95% CI, 0.78-58.57, P 5 0.08). The association of MSI2 with poorer outcomes indicates that MSI2 may be an early marker of advanced CML disease.
Our work identifies the Musashi-Numb axis as an important regulator of myeloid leukaemia and indicates that maintenance of the immature state is dependent on reversal of classical differentiation cues. Specifically, we find that MSI2 is upregulated and NUMB downregulated as chronic phase CML progresses to blast crisis, and that modulation of this pathway can inhibit disease (Fig. 4g ). Although previous work has implicated Musashi and Numb in normal development 13, 14, 23, 24 , to our knowledge this is the first demonstration that this pathway is required for haematological malignancy.
Our previous work showing that whereas BCR-ABL cannot affect the choice between asymmetric and symmetric division, NUP98-HOXA9 can trigger a bias towards symmetric renewal 15 , had led us LETTERS to propose that regulators of asymmetric division might regulate leukaemic differentiation, and could thus be targets for therapy in advanced myeloid leukaemia. Our current work supports this and shows that Numb, which drives commitment and differentiation, can impair blast crisis CML establishment and propagation. It should be noted that just as Numb's influence may be mediated through p53 and/or Notch signalling 12, 13, 20 , Musashi may act through Numb as well as other targets such as p21 WAF1 (refs 21, 28) . Because blast crisis CML is uniformly resistant to current treatments, it is critical to identify new pathways that drive this aggressive disease. In that context, our work is important because it shows that specific differentiation cues associated with the Musashi-Numb cascade can unlock the differentiation potential of blast crisis CML and impair its growth. These data, together with the fact that Musashi seems to be an early marker of advanced CML, indicate that its expression could serve as a prognostic tool, and that targeting it might represent a new approach to therapy. Finally, reports of increased expression of Musashi in glioblastoma 29 and decreased expression of NUMB in high-grade breast cancer 30 raise the possibility that this pathway may also be relevant in solid cancers.
METHODS SUMMARY
Mouse models of CML were generated by transducing bone marrow stem and progenitor cells with retroviruses carrying BCR-ABL (chronic phase) or BCR-ABL and NUP98-HOXA9 (blast crisis phase) and transplanting them into irradiated recipient mice. The development of CML was confirmed by flow cytometry and histopathology. For Msi2 knockdown experiments, lineage-negative blast crisis CML cells were infected with Msi2 or control Luciferase shRNA retroviral constructs and leukaemia incidence monitored. Chromatin immunoprecipitation (ChIP) assays were performed using the myeloid leukaemia cell line M1. DNA was crosslinked and immunoprecipitated with control or anti-HOXA9 antibodies and analysed by PCR for regions of interest. CML patient samples were obtained from the Korean Leukaemia Bank (Korea), the Hammersmith MRD Lab Sample Archive (United Kingdom), the Fred Hutchinson Cancer Research Center (United States) and the Singapore General Hospital (Singapore). Gene expression in human chronic and blast crisis CML was analysed by PCR or by DNA microarrays.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
